Filing Flows › Ionis Pharmaceuticals (IONS) › Q2 2026 › vs Q1 2026
Ionis Pharmaceuticals (IONS) Q2 2026 vs Q1 2026 (quarter over quarter)
Ionis Pharmaceuticals's revenue rose $21.9M (+9%) from $246M in Q1 2026 to $268M in Q2 2026.
Ionis Pharmaceuticals, Q2 2026: revenue $268M (-41% year over year), operating margin -38.2%, net loss $115M, operating cash flow $566M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 205.1% | -331.0% | +536.1 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $268M | $246M | $21.9M | +9% |
| Net loss | $115M | $92.5M | $22.1M | +24% |
| Costs & expenses | $383M | $364M | $18.9M | +5% |
| Operating costs | $370M | $364M | $6.7M | +2% |
| Interest & other, net | $11.1M | −$25.1M | $36.2M | — |
| Income tax | $1.3M | $218K | $1.0M | +480% |
| Cost of revenue | $2.7M | $3.0M | −$244K | -8% |
| SG&A | $150M | $150M | $37K | 0% |
| Other operating costs | $217M | $210M | $6.9M | +3% |
| Operating cash sources | $680M | −$700M | $1.4B | — |
| Depreciation & amortization | $4.1M | $4.0M | $171K | +4% |
| Share-based compensation | $45.6M | $43.3M | $2.3M | +5% |
| Working capital & other | $630M | −$748M | $1.4B | — |
| Net loss absorbed | $115M | $92.5M | $22.1M | +24% |
| Operating cash flow | $566M | −$793M | $1.4B | — |
| Free cash flow (OCF − capex) | $549M | −$815M | $1.4B | — |
| Capital expenditures | $16.1M | $21.8M | −$5.7M | -26% |
Questions
How much did Ionis Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Ionis Pharmaceuticals's revenue rose $21.9M (+9%) from $246M in Q1 2026 to $268M in Q2 2026.